Entacapone enhances Levodopa-induced reversal of motor disability in MPTP-Treated common marmosets

Movement Disorders

Volumn 12, Issue 6, 1997, Pages 935-945

  Smith, Lance A ^a   Gordin, Ariel ^b   Jenner, Peter ^a   Marsden, C David ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ORION CORPORATION   (Finland)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Behavioral disability; Carbidopa; COMT inhibitor; Entacapone; Levodopa; Locomotor activity; MPTP

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; FEMALE; LOCOMOTION; MALE; MARMOSET; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSONISM; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CALLITHRIX; CARBIDOPA; CATECHOLS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; LEVODOPA; MALE; MOVEMENT DISORDERS; SEVERITY OF ILLNESS INDEX;

EID: 0030668631     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870120616     Document Type: Article

References (18)

1. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984; 34:1131-1136.
2. Cedarbaum JM. Clinical pharmacokinetics of antiparkinsonian drugs, Clin Pharmacokinet 1987;13:141-178.
3. Männistö FT, Ulmanen I, Lundstrom K. Characteristics of catechol-O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992;39:291-350.
4. Männistö PT, Kaakkola S. New selective COMT inhibitors as useful adjuncts for Parkinson's disease? Trends Pharmacol Sci 1989;10:54-56.
5. Sharples NS, Tyce GM, Owen CA. Effect of chronic administration of L-dopa on catechol-O-methyltransferase in rat tissues. Life Sci 1973;12:97-106.
6. Nissinen E, Tuominen R, Perhoniemi V, Kaakkola S. Catechol-O-methyltransferase activity in human and rat small intestines. Life Sci 1988;42:2609-2614.
7. Guldeberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 1975; 27:135-206.
8. Männistö PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 1990;66:317-323.
9. Nissinen E, Lindén IB, Shultz E, Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schimiedebergs Arch Pharmacol 1992;346:262-266.
10. Kaakkola S, Gordin A, Mönnistö PT. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 1994;25:813-824.
11. Guttman M, Leger G, Reches A, et al. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov Disord 1993;8:298-304.
12. Cedarbaum JM, Leger G, Guttman M. Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyldopa with OR-611 and OR-642 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. Clin Neuropharmacol 1991;14: 330-342.
13. Merello M, Lees A, Webster R, et al. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Nenrosurg Psychiatry 1994;57:186-189.
14. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
15. Törnwall M, Männistö FT. Effects of three types of catecholmethylation inhibitors on L-3,4,-dihydroxyphenylalanine-induced behaviour in rats. Eur J Pharmacol 1993;250:77-84.
16. Nomoto M, Jenner P, Marsden CD. The D-1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D-2 agonist LY 171555 in the MPTP-treated marmoset. Neurosci Lett 1988;93:275-280.
17. Kebabian JW, Britton DR, De Ninno MP, et al. A77636: a potent and selective dopamine D-1 receptor agonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 1992;229:203-209.
18. Löschmann P, Smith LA, Lange KW, et al. Motor activity following administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology (Berlin) 1992;109:49-56.